Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14

被引:24
作者
Shou, Yuwei [1 ,2 ]
Wang, Xiaoqian [3 ]
Liang, Yinghao [3 ]
Liu, Xiaonan [1 ]
Chen, Kuisheng [2 ]
机构
[1] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Dept Pathol, Affiliated Hosp 1, 1 Jianshedong Rd, Zhengzhou 450000, Henan, Peoples R China
[3] Zhengzhou Univ, Henan Key Lab Tumor Pathol, Zhengzhou, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
Exosomes; miR-154-5p; kinesin family member 14 (KIF14); esophageal squamous cell carcinoma (ESCC); angiogenesis; PROLIFERATION; KIF14; INVASION; MIGRATION; PROTEINS;
D O I
10.1080/21655979.2022.2037322
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Exosomes participate in the progression and angiogenesis of esophageal squamous cell carcinoma (ESCC). This study aimed to explore the effect and mechanism of exosomes-derived miR-154-5p on the progression and angiogenesis of ESCC. The exosomes with the diameter of 40-270 nm were successfully isolated from ESCC cells by ultracentrifugation. They were then assessed by transmission electron microscope (TEM), nanoparticle tracking analysis (NTA), and Western blotting. Kinesin family member 14 (KIF14) was upregulated, while miR-154-5p was downregulated in ESCC as examined by Quantitative Real-time PCR (qRT-PCR). Exosomes-derived miR-154-5p from ESCC cells was found to attenuate the cellular migration, invasion, and angiogenesis of ESCC using Cell Counting Kit-8 (CCK-8), wound healing assay, transwell migration assay, and tumor formation assays. Moreover, KIF14 was proven to be a direct downstream target gene of miR-154-5p in ESCC cells using luciferase assay. In conclusion, our study identified that exosomes-derived miR-154-5p attenuates ESCC progression and angiogenesis by targeting KIF14 in vitro, which might provide a novel approach for the diagnosis and treatment of ESCC.
引用
收藏
页码:4610 / 4620
页数:11
相关论文
共 35 条
[1]   Epidemiology of Esophageal Squamous Cell Carcinoma [J].
Abnet, Christian C. ;
Arnold, Melina ;
Wei, Wen-Qiang .
GASTROENTEROLOGY, 2018, 154 (02) :360-373
[2]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[3]   Proteomic Analysis of Exosomes from Mutant KRAS Colon Cancer Cells Identifies Intercellular Transfer of Mutant KRAS [J].
Beckler, Michelle Demory ;
Higginbotham, James N. ;
Franklin, Jeffrey L. ;
Ham, Amy-Joan ;
Halvey, Patrick J. ;
Imasuen, Imade E. ;
Whitwell, Corbin ;
Li, Ming ;
Liebler, Daniel C. ;
Coffey, Robert J. .
MOLECULAR & CELLULAR PROTEOMICS, 2013, 12 (02) :343-355
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure [J].
Carleton, M ;
Mao, M ;
Biery, M ;
Warrener, P ;
Kim, S ;
Buser, C ;
Marshall, CG ;
Fernandes, C ;
Annis, J ;
Linsley, PS .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (10) :3853-3863
[6]   MiR-154-5p Suppresses Cell Invasion and Migration Through Inhibiting KIF14 in Nasopharyngeal Carcinoma [J].
Chen, Jie ;
Ma, Chengxian ;
Zhang, Yufeng ;
Pei, Shuai ;
Du, Mingyu ;
Zhang, Yujie ;
Qian, Luxi ;
Wang, Jianlin ;
Yin, Li ;
He, Xia .
ONCOTARGETS AND THERAPY, 2020, 13 :2235-2246
[7]   SNHG5 Promotes Breast Cancer Proliferation by Sponging the miR-154-5p/PCNA Axis [J].
Chi, Jiang-Rui ;
Yu, Zhi-Hao ;
Liu, Bo-Wen ;
Zhang, Di ;
Ge, Jie ;
Yu, Yue ;
Cao, Xu-Chen .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 17 :138-149
[8]   KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers [J].
Corson, TW ;
Huang, A ;
Tsao, MS ;
Gallie, BL .
ONCOGENE, 2005, 24 (30) :4741-4753
[9]   miR-378a-3p exerts tumor suppressive function on the tumorigenesis of esophageal squamous cell carcinoma by targeting Rab10 [J].
Ding, Naixin ;
Sun, Xiujin ;
Wang, Tingting ;
Huang, Lei ;
Wen, Jing ;
Zhou, Yiqin .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (01) :381-391
[10]  
Gao DC, 2020, EUR REV MED PHARMACO, V24, P6097, DOI 10.26355/eurrev_202006_21505